Barij Nayan Sinha

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5534180/publications.pdf

Version: 2024-02-01

75 papers	1,419 citations	346980 22 h-index	425179 34 g-index
77 all docs	77 docs citations	77 times ranked	2082 citing authors

#	Article	IF	Citations
1	Mycobactin Analogues with Excellent Pharmacokinetic Profile Demonstrate Potent Antitubercular Specific Activity and Exceptional Efflux Pump Inhibition. Journal of Medicinal Chemistry, 2022, 65, 234-256.	2.9	11
2	Two new anticancer phenolic derivatives from leaves of Piper betle Linn.. Natural Product Research, 2021, 35, 5021-5029.	1.0	10
3	A short survey of dengue protease inhibitor development in the past 6Âyears (2015â€“2020) with an emphasis on similarities between DENV and SARS-CoV-2 proteases. Bioorganic and Medicinal Chemistry, 2021, 49, 116415.	1.4	10
4	Identification of Dengue NS2B-NS3 Protease Inhibitors Through High-Throughput Virtual Screeningâ€”Impacts on Drug Development Against the Dengue Virus. , 2021, , 93-120.		0
5	The Mycobactin Biosynthesis Pathway: A Prospective Therapeutic Target in the Battle against Tuberculosis. Journal of Medicinal Chemistry, 2021, 64, 71-100.	2.9	32
6	A Critical Observation on the Design and Development of Reported Peptide Inhibitors of DENV NS2B-NS3 Protease in the Last Two Decades. Mini-Reviews in Medicinal Chemistry, 2021, 21, .	1.1	0
7	The new ether derivative of phenylpropanoid and bioactivity was investigated from the leaves of Piper betle L.. Natural Product Research, 2020, 34, 638-645.	1.0	11
8	Quinazolinone derivative BNUAâ€3 ameliorated [NDEA+2â€AAF]â€induced liver carcinogenesis in SD rats by modulating AhRâ€CYP1B1â€Nrf2â€Keap1 pathway. Clinical and Experimental Pharmacology and Physiology, 2020, 47, 143-157.	0.9	11
9	A novel druggable interprotomer pocket in the capsid of rhino- and enteroviruses. PLoS Biology, 2019, 17, e3000281.	2.6	36
10	CYP enzymes, expressed within live human suspension cells, are superior to widely-used microsomal enzymes in identifying potent CYP1A1/CYP1B1 inhibitors: Identification of quinazolinones as CYP1A1/CYP1B1 inhibitors that efficiently reverse B[a]P toxicity and cisplatin resistance. European Journal of Pharmaceutical Sciences, 2019, 131, 177-194.	1.9	11
11	Phytoestrogens and their synthetic analogues as substrate mimic inhibitors of CYP1B1. European Journal of Medicinal Chemistry, 2019, 163, 28-36.	2.6	8
12	Cink4T, a quinazolinone-based dual inhibitor of Cdk4 and tubulin polymerization, identified via ligand-based virtual screening, for efficient anticancer therapy. European Journal of Medicinal Chemistry, 2019, 165, 115-132.	2.6	28
13	New chemical constituents from the Piper betle Linn. (Piperaceae). Natural Product Research, 2018, 32, 1080-1087.	1.0	23
14	Comparative Shape and Electrostatic Study of Highly Potent and Selective CYP1B1 Inhibitor: Assessment of Active Site of CYP1B1 by Binding Mode Analysis Using Site Map Tool. Indian Journal of Pharmaceutical Education and Research, 2018, 52, 159-165.	0.3	2
15	Crystal structures and Hirshfeld surface analyses of 2-[(4,6-diaminopyrimidin-2-yl)sulfanyl]-N-(pyridin-2-yl)acetamide and 2-[(4,6-diaminopyrimidin-2-yl)sulfanyl]-N-(pyrazin-2-yl)acetamide. Acta Crystallographica Section E: Crystallographic Communications, 2018, 74, 718-723.	0.2	0
16	Quinazoline derivatives as selective CYP1B1 inhibitors. European Journal of Medicinal Chemistry, 2017, 130, 320-327.	2.6	37
17	Design, synthesis and MAO inhibitory activity of 2-(arylmethylidene)-2,3-dihydro-1-benzofuran-3-one derivatives. Chinese Chemical Letters, 2017, 28, 1528-1532.	4.8	21
18	Bioactive phenylpropanoid analogues from Piper betle L. var. birkoli leaves. Natural Product Research, 2017, 31, 2604-2611.	1.0	12

#	Article	IF	Citations
19	Crystal structures of 2-[(4,6-diaminopyrimidin-2-yl)sulfanyl]-N-(2,4-dimethylphenyl)acetamide and 2-[(4,6-diaminopyrimidin-2-yl)sulfanyl]-N-(3-methoxyphenyl)acetamide. Acta Crystallographica Section E: Crystallographic Communications, 2017, 73, 996-1000.	0.2	2
20	Crystal structures ofN-(4-chlorophenyl)-2-[(4,6-diaminopyrimidin-2-yl)sulfanyl]acetamide andN-(3-chlorophenyl)-2-[(4,6-diaminopyrimidin-2-yl)sulfanyl]acetamide. Acta Crystallographica Section E: Crystallographic Communications, 2017, 73, 467-471.	0.2	3
21	Design, Synthesis and biological evaluation of diazeno-thiazole derivatives as ribonucleotide reductase inhibitors. Journal of Pharmaceutical Chemistry, 2017, 4, 20-24.	0.2	2
22	In silico development of a novel putative inhibitor of the 3C protease of Coxsackievirus B3 with a benzene sulfonamide skeleton. Journal of Pharmaceutical Chemistry, 2017, 4, 25-34.	0.2	1
23	Computer-Aided Structure Based Drug Design Approaches for the Discovery of New Anti-CHIKV Agents. Current Computer-Aided Drug Design, 2017, 13, 346-361.	0.8	4
24	Stability Indicating HPLC Method Using Core Shell Stationary Phase for the Determination of Related Substances in Levocetirizine Dihydrochloride Oral Solution. Indian Journal of Pharmaceutical Education and Research, 2017, 51, s769-s775.	0.3	2
25	Crystal structures of 2-[(4,6-diaminopyrimidin-2-yl)sulfanyl]-N-(naphthalen-1-yl)acetamide and 2-[(4,6-diaminopyrimidin-2-yl)sulfanyl]-N-(4-fluorophenyl)acetamide. Acta Crystallographica Section E: Crystallographic Communications, 2017, 73, 306-309.	0.2	2
26	Progress and prospects on DENV protease inhibitors. European Journal of Medicinal Chemistry, 2016, 117, 125-143.	2.6	45
27	Biphenyl urea derivatives as selective CYP1B1 inhibitors. Organic and Biomolecular Chemistry, 2016, 14, 8931-8936.	1.5	21
28	Monoamine Oxidase Inhibitory Activity of Ferulic Acid Amides: Curcuminâ€Based Design and Synthesis. Archiv Der Pharmazie, 2016, 349, 9-19.	2.1	24
29	Monoamine Oxidase Inhibitory Activity of Novel Pyrazoline Analogues: Curcumin Based Design and Synthesisâ€ . ChemistrySelect, 2016, 1, 5879-5884.	0.7	10
30	Monoamine Oxidase Inhibitory Activity of Novel Pyrazoline Analogues: Curcumin Based Design and Synthesis. ACS Medicinal Chemistry Letters, 2016, 7, 56-61.	1.3	52
31	Characterization of forced degradation products and in silico toxicity prediction of Sofosbuvir: A novel HCV NS5B polymerase inhibitor. Journal of Pharmaceutical and Biomedical Analysis, 2016, 120, 352-363.	1.4	41
32	Synthesis and Antidepressant activity of pyrazoline based MAO-inhibitors. Journal of Pharmaceutical Chemistry, 2016, 3, 1-3.	0.2	11
33	Synthesis and Antiviral Activity of 2-aryl-4H-chromen-4-one Derivatives Against Chikungunya Virus. Letters in Drug Design and Discovery, 2016, 13, 1019-1024.	0.4	12
34	A rapid and sensitive determination of hypoxic radiosensitizer agent nimorazole in rat plasma by LCâ€MS/MS and its application to a pharmacokinetic study. Biomedical Chromatography, 2015, 29, 1575-1580.	0.8	5
35	Design, synthesis, optimization and antiviral activity of a class of hybrid dengue virus E protein inhibitors. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1747-1752.	1.0	34
36	Simultaneous Determination and Pharmacokinetics of Metolazone, Losartan and Losartan Carboxylic Acid in Rat Plasma by HPLCâ€“ESIâ€“MS-MS. Journal of Chromatographic Science, 2015, 53, 1520-1527.	0.7	9

#	Article	IF	Citations
37	Synthesis and molecular modelling studies of novel sulphonamide derivatives as dengue virus 2 protease inhibitors. Bioorganic Chemistry, 2015, 62, 74-82.	2.0	34
38	Ficus religiosa L. bark extracts inhibit human rhinovirus and respiratory syncytial virus infection in vitro. Journal of Ethnopharmacology, 2015, 176, 252-257.	2.0	20
39	Monoamine oxidase inhibitory activity of 2-aryl-4H-chromen-4-ones. Bioorganic Chemistry, 2015, 58, 72-80.	2.0	41
40	Physicochemical and drug release characteristics of acetylated starches of five Lagenaria siceraria cultivars. International Journal of Biological Macromolecules, 2015, 72, 1005-1012.	3.6	11
41	Thiazolidone derivatives as inhibitors of chikungunya virus. European Journal of Medicinal Chemistry, 2015, 89, 172-178.	2.6	52
42	Pyrazoline carboxylates as selective MAO-B inhibitors: Synthesis and Biological screening. Journal of Pharmaceutical Chemistry, 2015, 2, 1-5.	0.2	7
43	Monoamine oxidase-A inhibitory activity of novel Curcumin analogues. Journal of Pharmaceutical Chemistry, 2015, 2, 12.	0.2	4
44	Histone Deacetylase Inhibitors: A Review on Class-I Specific Inhibition. Mini-Reviews in Medicinal Chemistry, 2015, 15, 731-750.	1.1	20
45	Identification of Pyrazole Derivative as an Antiviral Agent Against Chikungunya Through HTVS. Letters in Drug Design and Discovery, 2015, 12, 292-301.	0.4	16
46	Isolation and Evaluation of the Enantiospecific Antitubercular Activity of a Novel Triazole Compound. Scientia Pharmaceutica, 2014, 82, 87-97.	0.7	1
47	Chiral HPLC Method for the Novel Triazole Antitubercular Compound MSDRT 12. Chromatographia, 2014, 77, 511-516.	0.7	2
48	Modified release and antioxidant stable Lagenaria siceraria extract microspheres using co-precipitated starch. International Journal of Biological Macromolecules, 2014, 66, 40-45.	3.6	5
49	Synthesis, characterization and evaluation of release retardant modified starches of Lagenaria siceraria seeds. International Journal of Biological Macromolecules, 2013, 61, 396-403.	3.6	21
50	Pharmacognostic specifications of eight cultivars of Piper betle fromÂeastern region of India. Pharmacognosy Journal, 2013, 5, 176-183.	0.3	10
51	Monoamine oxidase inhibitory activity of 3,5-biaryl-4,5-dihydro-1H-pyrazole-1-carboxylate derivatives. European Journal of Medicinal Chemistry, 2013, 69, 762-767.	2.6	53
52	Î³-Amino butyric acid analogs as novel potent GABA-AT inhibitors: molecular docking, synthesis, and biological evaluation. Medicinal Chemistry Research, 2013, 22, 134-146.	1.1	8
53	Radical Scavengers as Ribonucleotide Reductase Inhibitors. Current Topics in Medicinal Chemistry, 2013, 12, 2827-2842.	1.0	4
54	Hydroxamates as Ribonucleotide Reductase Inhibitors. , 2013, , 153-172.		0

#	Article	IF	Citations
55	Understanding the molecular interactions of different radical scavengers with ribonucleotide reductase M2 (hRRM2) domain: opening the gates and gaining access. Journal of Computer-Aided Molecular Design, 2012, 26, 865-881.	1.3	1
56	Effect of substitution at Nâ€³-position of Nâ€²-hydroxy-N-amino guanidines on tumor cell growth. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 4934-4938.	1.0	3
57	A novel N-hydroxy-Nâ€²-aminoguanidine derivative inhibits ribonucleotide reductase activity: Effects in human HL-60 promyelocytic leukemia cells and synergism with arabinofuranosylcytosine (Ara-C). Biochemical Pharmacology, 2011, 81, 50-59.	2.0	12
58	Chemical scaffolds with structural similarities to siderophores of nonribosomal peptideâ€“polyketide origin as novel antimicrobials against Mycobacterium tuberculosis and Yersinia pestis. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6533-6537.	1.0	19
59	QSAR and docking-based computational chemistry approach to novel GABA-AT inhibitors: kNN-MFA-based 3DQSAR model for phenyl-substituted analogs of Î²-phenylethylidene hydrazine. Medicinal Chemistry Research, 2011, 20, 549-553.	1.1	5
60	Novel GABA-AT inhibitors: QSAR and docking based virtual screening of phenyl substituted Î²-phenyl ethylidene hydrazine analogues. Medicinal Chemistry Research, 2011, 20, 1482-1489.	1.1	6
61	N-Hydroxy-Nâ€²-aminoguanidines as anti-cancer lead molecule: QSAR, synthesis and biological evaluation. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 3324-3328.	1.0	17
62	Pyrazoline based MAO inhibitors: Synthesis, biological evaluation and SAR studies. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 4296-4300.	1.0	39
63	Virtual screening studies on HIV-1 reverse transcriptase inhibitors to design potent leads. European Journal of Medicinal Chemistry, 2011, 46, 851-859.	2.6	17
64	Antidiarrheal activity of Capparis zeylanica leaf extracts. Journal of Advanced Pharmaceutical Technology and Research, 2011, 2, 39.	0.4	7
65	Development of selective and reversible pyrazoline based MAO-A inhibitors: Synthesis, biological evaluation and docking studies. Bioorganic and Medicinal Chemistry, 2010, 18, 1875-1881.	1.4	48
66	Inhibitors of Human Histone Deacetylase: Synthesis and Enzyme Assay of Hydroxamates with Piperazine Linker. Archiv Der Pharmazie, 2010, 343, 167-172.	2.1	7
67	Towards development of selective and reversible pyrazoline based MAO-inhibitors: Synthesis, biological evaluation and docking studies. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 132-136.	1.0	66
68	Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 3906-3910.	1.0	45
69	Fragment and knowledge-based design of selective GSK-3Î² inhibitors using virtual screening models. European Journal of Medicinal Chemistry, 2009, 44, 2361-2371.	2.6	27
70	Pharmacophore modeling and virtual screening studies to design some potential histone deacetylase inhibitors as new leads. Journal of Molecular Graphics and Modelling, 2008, 26, 935-946.	1.3	71
71	Pyrazoline-based mycobactin analogues as MAO-inhibitors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 6362-6368.	1.0	50
72	Small molecules with structural similarities to siderophores as novel antimicrobials against Mycobacterium tuberculosis and Yersinia pestis. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2662-2668.	1.0	57

#	Article	IF	Citations
73	Antiinflammatory, diuretic and antimicrobial activities of <i> Rungia pectinata</i> linn. and <i> Rungia repens</i> nees. Indian Journal of Pharmaceutical Sciences, 2008, 70, 679.	1.0	14
74	Virtual Screening Studies to Design Potent CDK2-Cyclin A Inhibitors. Journal of Chemical Information and Modeling, 2007, 47, 1526-1535.	2.5	56
75	Central analgesic activity of Litsea polyantha Juss. bark extract. , 0, , .		0